Doxycycline hyclate controlled-release - CollaGenex Pharmaceuticals

Drug Profile

Doxycycline hyclate controlled-release - CollaGenex Pharmaceuticals

Alternative Names: Controlled-release doxycycline hyclate; Doxycycline hyclate sustained release - CollaGenex/Shire; Periostat II; Periostat MR; Periostat SR; Sustained-release doxycycline hyclate - CollaGenex

Latest Information Update: 04 Feb 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CollaGenex Pharmaceuticals
  • Developer Supernus Pharmaceuticals
  • Class Antibacterials; Collagenases; Skin disorder therapies; Tetracyclines
  • Mechanism of Action Collagenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Periodontal disorders

Most Recent Events

  • 23 Nov 2004 CollaGenex has completed enrolment in a phase III trial for adult periodontitis in the US and UK
  • 05 Apr 2004 Phase-III clinical trials in Periodontal disorders in United Kingdom (PO)
  • 05 Apr 2004 Phase-III clinical trials in Periodontal disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top